Page 72 - ஆரோக்கியம் பராமரிப்பு தொழிலாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Health Ministry issues advisory of potential thromboembolic incidents Adverse Event Following Immunisation (AEFI) data in India showed that there is a minuscule but definitive risk of thromboembolic events after the AstraZeneca-Oxford vaccine (Covishield in India). A statement issued by the Health Ministry on Monday noted that the reporting rate of these events in India is around 0.61/million doses, which is much lower than the four cases/million reported by UK’s regulator Medical and Health Regulatory Authority (MHRA). Germany has reported 10 events per million doses. There were no potential thromboembolic events reported following administration of Covaxin vaccine. Bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country, a report submitted by the National AEFI to the Health Ministry noted.

United kingdomHealth regulatory authorityHealth ministry onHealth ministryAdverse event following immunisationSoutheast asianHealth care workersVaccine beneficiariesCovishield blood clottingCovishield bleedingAefi dataThromboembolic eventsAstrazeneca oxford vaccineஒன்றுபட்டது கிஂக்டம்ஆரோக்கியம் ஒழுங்குமுறை அதிகாரம்ஆரோக்கியம் அமைச்சகம் ஆன்